DOV Pharmaceutical, Inc. has announced phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity.
From: www.pharmabiz.com
DOV Pharma says its depression drug is safe
Posted by Ruslan Abuzant at 1:08 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment